Medicare’s new technology bonus payments
CMS is proposing a July 1 FDA approval deadline for products that are candidates for extra reimbursement under Medicare's inpatient payment rules. Medicare boosts hospital reimbursement for technologies that have been on the market for less than three years, demonstrate "substantial clinical improvement" over existing therapies, and would not be adequately reimbursed by Medicare. CMS says a July deadline would allow time for adequate review and avoid devoting resources to in-depth evaluation of products that do not come to market in time for a final decision by Oct. 1, when the add-on payments take effect. The change is outlined in proposed rules governing the Medicare inpatient prospective payment system for FY 2009, slated for Federal Register publication April 30
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.